Multivariate COX regression analysis for the prediction of all-cause mortality and cardiovascular mortality
| . | . | eGFR (EKFC equation) . | eGFR (CKD-EPI equation) . |
|---|---|---|---|
| . | . | HR (95% CI) . | HR (95% CI) . |
| All-cause mortality | |||
| Model 1 | ≥120 | 1.67 (0.94–2.98) | 2.24 (1.76–2.85)*** |
| ≥90, <120 | 1.28 (1.15–1.42) *** | 1.10 (1.02–1.19) * | |
| ≥60, <90 | 1 (ref.) | 1 (ref.) | |
| <60 | 1.47 (1.38–1.56)*** | 1.53 (1.44–1.62)*** | |
| Model 2 | ≥120 | 1.64 (0.84–3.19) | 2.21 (1.68–2.92)*** |
| ≥90, <120 | 1.28 (1.14–1.44) *** | 1.16 (1.06–1.27) ** | |
| ≥60, <90 | 1 (ref.) | 1 (ref.) | |
| <60 | 1.21 (1.13–1.30)*** | 1.27 (1.18–1.36)*** | |
| Cardiovascular mortality | |||
| Model 1 | ≥120 | 1.01 (0.14–7.30) | 2.38 (1.30–4.35) ** |
| ≥90, <120 | 1.26 (1.01–1.59) * | 1.02 (0.86–1.21) | |
| ≥60, <90 | 1 (ref.) | 1 (ref.) | |
| <60 | 1.73 (1.54–1.94) *** | 1.69 (1.51–1.89)*** | |
| Model 2 | ≥120 | 1.48 (0.20–10.83) | 3.17 (1.66–6.06)*** |
| ≥90, <120 | 1.33 (1.03–1.73) * | 1.14 (0.93–1.38) | |
| ≥60, <90 | 1 (ref.) | 1 (ref.) | |
| <60 | 1.26 (1.11–1.45)*** | 1.26 (1.10–1.44)*** |
| . | . | eGFR (EKFC equation) . | eGFR (CKD-EPI equation) . |
|---|---|---|---|
| . | . | HR (95% CI) . | HR (95% CI) . |
| All-cause mortality | |||
| Model 1 | ≥120 | 1.67 (0.94–2.98) | 2.24 (1.76–2.85)*** |
| ≥90, <120 | 1.28 (1.15–1.42) *** | 1.10 (1.02–1.19) * | |
| ≥60, <90 | 1 (ref.) | 1 (ref.) | |
| <60 | 1.47 (1.38–1.56)*** | 1.53 (1.44–1.62)*** | |
| Model 2 | ≥120 | 1.64 (0.84–3.19) | 2.21 (1.68–2.92)*** |
| ≥90, <120 | 1.28 (1.14–1.44) *** | 1.16 (1.06–1.27) ** | |
| ≥60, <90 | 1 (ref.) | 1 (ref.) | |
| <60 | 1.21 (1.13–1.30)*** | 1.27 (1.18–1.36)*** | |
| Cardiovascular mortality | |||
| Model 1 | ≥120 | 1.01 (0.14–7.30) | 2.38 (1.30–4.35) ** |
| ≥90, <120 | 1.26 (1.01–1.59) * | 1.02 (0.86–1.21) | |
| ≥60, <90 | 1 (ref.) | 1 (ref.) | |
| <60 | 1.73 (1.54–1.94) *** | 1.69 (1.51–1.89)*** | |
| Model 2 | ≥120 | 1.48 (0.20–10.83) | 3.17 (1.66–6.06)*** |
| ≥90, <120 | 1.33 (1.03–1.73) * | 1.14 (0.93–1.38) | |
| ≥60, <90 | 1 (ref.) | 1 (ref.) | |
| <60 | 1.26 (1.11–1.45)*** | 1.26 (1.10–1.44)*** |
Model 1: adjusted for age and sex.
Model 2: adjusted for age, sex, ethnicity, education level, diabetes mellitus, smoker, alcohol user, systolic BP, diastolic BP, BMI, coronary heart disease, congestive heart failure, stroke, cancer, emphysema/chronic bronchitis, ACEI/ARB, beta-blockers, CCBs, diuretics, statins, and aspirin.
CI, confidence interval; CKD-EPI, Chronic Kidney Disease Epidemiology Collaboration; eGFR, estimated glomerular filtration rate; EKFC, European Kidney Function Consortium; HDL, high-density lipoprotein; HR, hazard ratio; LDL, low-density lipoprotein. * represents P < 0.05, ** represents P < 0.01, *** represents P < 0.001.
Multivariate COX regression analysis for the prediction of all-cause mortality and cardiovascular mortality
| . | . | eGFR (EKFC equation) . | eGFR (CKD-EPI equation) . |
|---|---|---|---|
| . | . | HR (95% CI) . | HR (95% CI) . |
| All-cause mortality | |||
| Model 1 | ≥120 | 1.67 (0.94–2.98) | 2.24 (1.76–2.85)*** |
| ≥90, <120 | 1.28 (1.15–1.42) *** | 1.10 (1.02–1.19) * | |
| ≥60, <90 | 1 (ref.) | 1 (ref.) | |
| <60 | 1.47 (1.38–1.56)*** | 1.53 (1.44–1.62)*** | |
| Model 2 | ≥120 | 1.64 (0.84–3.19) | 2.21 (1.68–2.92)*** |
| ≥90, <120 | 1.28 (1.14–1.44) *** | 1.16 (1.06–1.27) ** | |
| ≥60, <90 | 1 (ref.) | 1 (ref.) | |
| <60 | 1.21 (1.13–1.30)*** | 1.27 (1.18–1.36)*** | |
| Cardiovascular mortality | |||
| Model 1 | ≥120 | 1.01 (0.14–7.30) | 2.38 (1.30–4.35) ** |
| ≥90, <120 | 1.26 (1.01–1.59) * | 1.02 (0.86–1.21) | |
| ≥60, <90 | 1 (ref.) | 1 (ref.) | |
| <60 | 1.73 (1.54–1.94) *** | 1.69 (1.51–1.89)*** | |
| Model 2 | ≥120 | 1.48 (0.20–10.83) | 3.17 (1.66–6.06)*** |
| ≥90, <120 | 1.33 (1.03–1.73) * | 1.14 (0.93–1.38) | |
| ≥60, <90 | 1 (ref.) | 1 (ref.) | |
| <60 | 1.26 (1.11–1.45)*** | 1.26 (1.10–1.44)*** |
| . | . | eGFR (EKFC equation) . | eGFR (CKD-EPI equation) . |
|---|---|---|---|
| . | . | HR (95% CI) . | HR (95% CI) . |
| All-cause mortality | |||
| Model 1 | ≥120 | 1.67 (0.94–2.98) | 2.24 (1.76–2.85)*** |
| ≥90, <120 | 1.28 (1.15–1.42) *** | 1.10 (1.02–1.19) * | |
| ≥60, <90 | 1 (ref.) | 1 (ref.) | |
| <60 | 1.47 (1.38–1.56)*** | 1.53 (1.44–1.62)*** | |
| Model 2 | ≥120 | 1.64 (0.84–3.19) | 2.21 (1.68–2.92)*** |
| ≥90, <120 | 1.28 (1.14–1.44) *** | 1.16 (1.06–1.27) ** | |
| ≥60, <90 | 1 (ref.) | 1 (ref.) | |
| <60 | 1.21 (1.13–1.30)*** | 1.27 (1.18–1.36)*** | |
| Cardiovascular mortality | |||
| Model 1 | ≥120 | 1.01 (0.14–7.30) | 2.38 (1.30–4.35) ** |
| ≥90, <120 | 1.26 (1.01–1.59) * | 1.02 (0.86–1.21) | |
| ≥60, <90 | 1 (ref.) | 1 (ref.) | |
| <60 | 1.73 (1.54–1.94) *** | 1.69 (1.51–1.89)*** | |
| Model 2 | ≥120 | 1.48 (0.20–10.83) | 3.17 (1.66–6.06)*** |
| ≥90, <120 | 1.33 (1.03–1.73) * | 1.14 (0.93–1.38) | |
| ≥60, <90 | 1 (ref.) | 1 (ref.) | |
| <60 | 1.26 (1.11–1.45)*** | 1.26 (1.10–1.44)*** |
Model 1: adjusted for age and sex.
Model 2: adjusted for age, sex, ethnicity, education level, diabetes mellitus, smoker, alcohol user, systolic BP, diastolic BP, BMI, coronary heart disease, congestive heart failure, stroke, cancer, emphysema/chronic bronchitis, ACEI/ARB, beta-blockers, CCBs, diuretics, statins, and aspirin.
CI, confidence interval; CKD-EPI, Chronic Kidney Disease Epidemiology Collaboration; eGFR, estimated glomerular filtration rate; EKFC, European Kidney Function Consortium; HDL, high-density lipoprotein; HR, hazard ratio; LDL, low-density lipoprotein. * represents P < 0.05, ** represents P < 0.01, *** represents P < 0.001.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
